The complex evolution of antibiotic resistance in Mycobacterium tuberculosis

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 94-100

  Fonseca, J D ^a   Knight, G M ^b   McHugh, T D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Drug resistance; Molecular mechanisms of resistance; Tuberculosis

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; DNA REPAIR; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; MULTIDRUG RESISTANCE; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; UPREGULATION; DRUG EFFECTS; EVOLUTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENETICS; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS;

BIOLOGICAL EVOLUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84925261260     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.01.014     Document Type: Review

References (100)

1. World Health Organization Global tuberculosis report 2014 2014.
2. Gandhi N.R., Nunn P., Dheda K., Schaaf H.S., Zignol M., Van Soolingen D., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
3. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., Khomenko A.G., Migliori G.B., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545.
4. Martinson N.A., Chaisson R.M. Survival in XDR TB: Shifting the Curve and Shifting the Paradigm. J Acquir Immune Defic Syndr 2011, 57:89.
5. Raviglione M. XDR-TB: entering the post-antibiotic era?. Int J Tuberc Lung Dis 2006, 10:1185-1187.
6. Pasipanodya J.G., Gumbo T. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 2011, 11:457-463.
7. Da Silva P.E.A., Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011, 66:1417-1430.
8. Louw G., Warren R., Van Pittius N.G., McEvoy C., Van Helden P., Victor T. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009, 53:3181-3189.
9. MacLean R.C., Hall A.R., Perron G.G., Buckling A. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat Rev Genet 2010, 11:405-414.
10. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., Bohannan B.J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
11. Borrell S., Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2011, 17:815-820.
12. Borrell S., Teo Y., Giardina F., Streicher E.M., Klopper M., Feldmann J., et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Publich Health 2013, 2013:65-74.
13. Chatterjee A., Saranath D., Bhatter P., Mistry N. Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One 2013, 8:e54717.
14. Farhat M.R., Shapiro B.J., Kieser K.J., Sultana R., Jacobson K.R., Victor T.C., et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 2013, 45:1183-1189.
15. Manjunatha U.H., Boshoff H., Dowd C.S., Zhang L., Albert T.J., Norton J.E., et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006, 103:431-436.
16. de Knegt G.J., Bruning O., ten Kate M.T., de Jong M., van Belkum A., Endtz H.P., et al. Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis. Tuberculosis (Edinb) 2013, 93:96-101.
17. Jiang X., Zhang W., Gao F., Huang Y., Lv C., Wang H. Comparison of the proteome of isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis. Microb Drug Resist 2006, 12:231-238.
18. Maus C.E., Plikaytis B.B., Shinnick T.M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:571-577.
19. Zhang H., Li D., Zhao L., Fleming J., Lin N., Wang T., et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 2013, 45:1255-1260.
20. Telenti A., Philipp W.J., Sreevatsan S., Bernasconi C., Stockbauer K.E., Wieles B., et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997, 3:567-570.
21. Safi H., Sayers B., Hazbon M.H., Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother 2008, 52:2027-2034.
22. Plinke C., Cox H.S., Zarkua N., Karimovich H.A., Braker K., Diel R., et al. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. J Antimicrob Chemother 2010, 65:1359-1367.
23. Safi H., Lingaraju S., Amin A., Kim S., Jones M., Holmes M., et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-beta-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 2013, 45:1190-1197.
24. Baquero F: Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat 2001, 4:93-105.
25. Safi H., Fleischmann R.D., Peterson S.N., Jones M.B., Jarrahi B., Alland D. Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010, 54:103-108.
26. Wong S.Y., Lee J.S., Kwak H.K., Via L.E., Boshoff H.I., Barry C.E. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011, 55:2515-2522.
27. Chopra I., O'Neill A.J., Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat 2003, 6:137-145.
28. Martinez J., Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000, 44:1771-1777.
29. Ebrahimi-Rad M., Bifani P., Martin C., Kremer K., Samper S., Rauzier J., et al. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis 2003, 9:838-845.
30. Stagg H.R., Cohen T., Becerra M.C., Anderson L.F., Abubakar I. A tale of two settings: the role of the Beijing genotype in the epidemiology of multidrug-resistant tuberculosis. Eur Respir J 2014, 43:632-635.
31. Lari N., Rindi L., Bonanni D., Tortoli E., Garzelli C. Mutations in mutT genes of Mycobacterium tuberculosis isolates of Beijing genotype. J Med Microbiol 2006, 55:599-603.
32. Ford C.B., Shah R.R., Maeda M.K., Gagneux S., Murray M.B., Cohen T., et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013, 45:784-790.
33. de Steenwinkel J.E., ten Kate M.T., de Knegt G.J., Kremer K., Aarnoutse R.E., Boeree M.J., et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg Infect Dis 2012, 18:660-663.
34. Saunders N.J., Trivedi U.H., Thomson M.L., Doig C., Laurenson I.F., Blaxter M.L. Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J Infect 2011, 62:212-217.
35. Sun G., Luo T., Yang C., Dong X., Li J., Zhu Y., et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis 2012, 206:1724-1733.
36. Merker M., Kohl T.A., Roetzer A., Truebe L., Richter E., Rüsch-Gerdes S., et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PloS One 2013, 8:e82551.
37. Dos Vultos T., Mestre O., Rauzier J., Golec M., Rastogi N., Rasolofo V., et al. Evolution and diversity of clonal bacteria: the paradigm of Mycobacterium tuberculosis. PloS one 2008, 3:e1538.
38. Gillespie S.H., Basu S., Dickens A.L., O'Sullivan D.M., McHugh T.D. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 2005, 56:344-348.
39. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997, 61:377-392.
40. O'Sullivan D.M., Hinds J., Butcher P.D., Gillespie S.H., McHugh T.D. Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin. J Antimicrob Chemother 2008, 62:1199-1202.
41. Boshoff H.I., Myers T.G., Copp B.R., McNeil M.R., Wilson M.A., Barry C.E. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action J Biol Chem 2004, 279:40174-40184.
42. Long R., Chong H., Hoeppner V., Shanmuganathan H., Kowalewska-Grochowska K., Shandro C., et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009, 48:1354-1360.
43. Deutschendorf C., Goldani L.Z., Santos R.P. Previous use of quinolones: a surrogate marker for first line anti-tuberculosis drugs resistance in HIV-infected patients?. Braz J Infect Dis 2012, 16:142-145.
44. Chen L.-C., Yeh H.-Y., Yeh C.-Y., Arias C.R., Soo V.-W. Identifying co-targets to fight drug resistance based on a random walk model. BMC Syst Biol 2012, 6:5.
45. Waddell S.J., Stabler R.A., Laing K., Kremer L., Reynolds R.C., Besra G.S. The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds. Tuberculosis 2004, 84:263-274.
46. Nohmi T. Environmental stress and lesion-bypass DNA polymerases. Annu Rev Microbiol 2006, 60:231-253.
47. Bergval I.L., Klatser P.R., Schuitema A.R., Oskam L., Anthony R.M. Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol Lett 2007, 275:338-343.
48. Boshoff H.I., Reed M.B., Barry C.E., Mizrahi V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 2003, 113:183-193.
49. Rossi E.D., Aínsa J.A., Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 2006, 30:36-52.
50. Gupta A.K., Katoch V.M., Chauhan D.S., Sharma R., Singh M., Venkatesan K., Sharma V.D. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist 2010, 16:21-28.
51. Jiang X., Zhang W., Zhang Y., Gao F., Lu C., Zhang X., Wang H. Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb Drug Resist 2008, 14:7-11.
52. Machado D., Couto I., Perdigao J., Rodrigues L., Portugal I., Baptista P., et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 2012, 7:e34538.
53. Louw G.E., Warren R.M., Gey van Pittius N.C., Leon R., Jimenez A., Hernandez-Pando R., et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Resp Crit Care Med 2011, 184:269-276.
54. Aínsa J.A., Blokpoel M.C., Otal I., Young D.B., De Smet K.A., Martín C. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 1998, 180:5836-5843.
55. Balganesh M., Kuruppath S., Marcel N., Sharma S., Nair A., Sharma U. Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob Agents Chemother 2010, 54:5167-5172.
56. Srivastava S., Musuka S., Sherman C., Meek C., Leff R., Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010, 201:1225-1231.
57. Webber M., Piddock L. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003, 51:9-11.
58. Viveiros M., Portugal I., Bettencourt R., Victor T.C., Jordaan A.M., Leandro C., et al. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002, 46:2804-2810.
59. Huitric E., Werngren J., Juréen P., Hoffner S. Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2006, 50:2860-2862.
60. Escribano I., Rodriguez J.C., Llorca B., Garcia-Pachon E., Ruiz M., Royo G. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 2007, 53:397-401.
61. Rodrigues L., Machado D., Couto I., Amaral L., Viveiros M. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol 2012, 12:695-700.
62. Spies F.S., da Silva P.E., Ribeiro M.O., Rossetti M.L., Zaha A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother 2008, 52:2947-2949.
63. Martins A., Iversen C., Rodrigues L., Spengler G., Ramos J., Kern W., et al. An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. Int J Antimicrob Agents 2009, 34:602-604.
64. Ramón-García S., Martín C., Thompson C.J., Aínsa J.A. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother 2009, 53:3675-3682.
65. Adams K.N., Takaki K., Connolly L.E., Wiedenhoft H., Winglee K., Humbert O., et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011, 145:39-53.
66. Rohde K.H., Abramovitch R.B., Russell D.G. Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2007, 2:352-364.
67. Mariam D.H., Mengistu Y., Hoffner S.E., Andersson D.I. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004, 48:1289-1294.
68. Billington O., McHugh T., Gillespie S. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43:1866-1869.
69. Gagneux S., Burgos M.V., DeRiemer K., Enciso A., Muñoz S., Hopewell P.C., et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS pathogens 2006, 2:e61.
70. Sherman D.R., Mdluli K., Hickey M.J., Arain T.M., Morris S.L., Barry C.E., et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996, 272:1641-1643.
71. Shcherbakov D., Akbergenov R., Matt T., Sander P., Andersson D.I., Böttger E.C. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010, 77:830-840.
72. De Vos M., Müller B., Borrell S., Black P., van Helden P., Warren R., et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 2013, 57:827-832.
73. Comas I., Borrell S., Roetzer A., Rose G., Malla B., Kato-Maeda M., et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2012, 44:106-110.
74. Casali N., Nikolayevskyy V., Balabanova Y., Ignatyeva O., Kontsevaya I., Harris S.R., et al. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res 2012, 22:735-745.
75. Brandis G., Wrande M., Liljas L., Hughes D. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 2012, 85:142-151.
76. Brandis G., Hughes D. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother 2013, 68:2493-2497.
77. Lanzas F., Karakousis P.C., Sacchettini J.C., Ioerger T.R. Multidrug-resistant tuberculosis in Panama is driven by clonal expansion of a multidrug-resistant Mycobacterium tuberculosis strain related to the KZN extensively drug-resistant M. tuberculosis strain from South Africa. J Clin Microbiol 2013, 51:3277-3285.
78. Trindade S., Sousa A., Xavier K.B., Dionisio F., Ferreira M.G., Gordo I. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet 2009, 5:e1000578.
79. Zaczek A., Brzostek A., Augustynowicz-Kopec E., Zwolska Z., Dziadek J. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 2009, 9:10.
80. Fenner L., Egger M., Bodmer T., Altpeter E., Zwahlen M., Jaton K., et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012, 56:3047-3053.
81. Spies F.S., Ribeiro A.W., Ramos D.F., Ribeiro M.O., Martin A., Palomino J.C., et al. Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. J Clin Microbiol 2011, 49:2625-2630.
82. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis drug resistance mutation database. PLoS medicine 2009, 6:e1000002.
83. Comas I., Chakravartti J., Small P.M., Galagan J., Niemann S., Kremer K., et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010, 42:498-503.
84. Baker L., Brown T., Maiden M.C., Drobniewski F. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg Infect Dis 2004, 10:1568-1577.
85. Bifani P.J., Mathema B., Kurepina N.E., Kreiswirth B.N. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002, 10:45-52.
86. Drobniewski F., Balabanova Y., Nikolayevsky V., Ruddy M., Kuznetzov S., Zakharova S., et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 2005, 293:2726-2731.
87. Borrell S., Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis State of the art. Int J Tuberc Lung Dis 2009, 13:1456-1466.
88. Baker L.V., Brown T.J., Maxwell O., Gibson A.L., Fang Z., Yates M.D., Drobniewski F.A. Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC -46A polymorphism. Antimicrob Agents Chemother 2005, 49:1455-1464.
89. van Doorn H.R., de Haas P.E., Kremer K., Vandenbroucke-Grauls C.M., Borgdorff M.W., van Soolingen D. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in the Netherlands. Clin Microbiol Infect 2006, 12:769-775.
90. Meacci F., Orrú G., Iona E., Giannoni F., Piersimoni C., Pozzi G., et al. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol 2005, 43:3114-3120.
91. Mariam S.H., Werngren J., Aronsson J., Hoffner S., Andersson D.I. Dynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatment. PLoS One 2011, 6:e21147.
92. van Rie A., Victor T.C., Richardson M., Johnson R., van der Spuy G.D., Murray E.J., et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005, 172:636-642.
93. Shamputa I.C., Jugheli L., Sadradze N., Willery E., Portaels F., Supply P., Rigouts L. Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res 2006, 7:99.
94. Cohen T., Sommers B., Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003, 3:13-21.
95. Zumla A., Nahid P., Cole S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
96. Bjorkman J., Andersson D.I. The cost of antibiotic resistance from a bacterial perspective. Drug Resist Updat 2000, 3:237-245.
97. Andersson D.I. The biological cost of mutational antibiotic resistance: any practical conclusions?. Curr Opin Microbiol 2006, 9::461-465.
98. Goldstein F. The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 2007, 59:1-4.
99. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 2014, 12:159-167.
100. Zetola N.M., Shin S.S., Tumedi K.A., Moeti K., Ncube R., Nicol M., et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol 2014, 52:2422-2430.